We are live on ! Find out more
TEVA icon

Teva Pharmaceuticals
TEVA

Fund managers haven’t disclosed any holdings of TEVA yet.

TEVA Hedge Fund Activity: Q1 2026 in Review

650 of the 8,125 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q1 2026, worth a combined $20.2B — down 6% from $21.4B a quarter earlier.

Buyers outnumbered sellers: 94 funds opened new TEVA positions and 64 closed out — a net gain of 30 holders — while 235 added to existing stakes and 196 trimmed.

The largest buyer was WCM Investment Management, adding an estimated $863M. The largest seller was Glenview Capital Management, cutting an estimated $324M.

  • 650 institutional investors held Teva Pharmaceuticals (TEVA) as of Q1 2026, up from 629 in Q4 2025.
  • Funds reported $20.2B of Teva Pharmaceuticals stock for Q1 2026, down 6% quarter-over-quarter.
  • 94 funds opened new Teva Pharmaceuticals positions in Q1 2026 and 64 closed out, a net change of +30 holders.
  • The largest Teva Pharmaceuticals buyer in Q1 2026 was WCM Investment Management, an estimated $863M added.
  • The largest Teva Pharmaceuticals seller in Q1 2026 was Glenview Capital Management, an estimated $324M sold.

Based on aggregated 13F filings for Q1 2026.